Globe Magazine profile of the reclusive investor and philanthropist who’d quietly bought up half of Harvard Square.

In a report released today, Judah Frommer from Morgan Stanley maintained a Sell rating on Galapagos (GLPG – Research Report), with a price ...

US biotech Merida Biosciences has launched with $121m in Series A financing to develop therapeutics targeting disease-causing ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Travere Therapeutics (TVTX – Research ...

The latest biotech to roll out of Third Rock Ventures is working on Fc-based therapeutics it hopes could offer new treatment ...

Gene therapy is an area of intensive research and development in the retina space, with promising prospects and significant challenges. The benefits and pitfalls of gene therapy were discussed by two ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The EMA’s human medicines committee refused marketing approvals for two drugs from Neuraxpharm and Apellis at its January meeting, but both companies have said they will appeal the decision.

Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Europe, with a more restricted label than in the US. The European ...